Straits Times Index
3,313.48 +8.49 (+0.26%) Nikkei
38,787.38 -132.88 (-0.34%) Hang Seng
19,553.61 +177.08 (+0.91%) FTSE 100
8,420.26 -18.39 (-0.22%) Bitcoin USD
66,748.05 +1,399.01 (+2.14%) CMC Crypto 200
1,363.50 -10.34 (-0.75%)
Bayer Aktiengesellschaft (0P6S.L)
| Previous close | 57.95 |
| Open | 58.54 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 56.91 - 57.16 |
| 52-week range | 46.72 - 65.65 |
| Volume | |
| Avg. volume | 841,216 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.97 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance UK
Stocks to watch this week: Burberry, Vodafone, BT and Walmart
Earnings preview of key companies reporting this week and what to look out for.
- Reuters SG
UPDATE 3-Singtel-owned Optus taps Rue as CEO to restore strategy and trust
Singapore Telecommunications-owned Optus said on Monday it had appointed Stephen Rue to lead the Australian phone carrier replacing former boss Kelly Bayer Rosmarin, who resigned in November post a nation-wide network outage last year. Rue has been running Australia's National Broadband Network (NBN) since 2018 and will now takeover as Optus CEO, as the firm seeks to reset its strategy and rebuild customer trust.
- Yahoo Finance Video
Bayer CEO: Now is not the time to break the company up
Life sciences company Bayer (BAYRY, BAYN.DE) isn't breaking itself up right now. Bayer CEO Bill Anderson says, "This is not a good time to be... breaking up the firm," given the company's need to rebuild its pharmaceutical pipeline and battle the ongoing litigation stemming from the weedkiller Roundup. When it comes to the Roundup lawsuits, Bayer has "adequately provisioned" for the costs of those suits, Anderson says. Overall, "the fundamental fact is, that glyphosate, Roundup, is safe," Anderson states, adding that Bayer is "a scientifically-driven company and we have this litigation thing that's not scientific." On the pharmaceutical business, Anderson says the group is "in a bit of a transition phase." "We got a couple of major medicines that are losing patent protection over the next few years. So we are busy rebuilding the pipeline right now," he tells Yahoo Finance. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Stephanie Mikulich.
